QIAGEN N.V. — FY2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide clear Q4-only financial results. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context
QIAGEN supplies molecular testing products and “Sample to Insight” solutions to clinical testing and life-sciences customers. Its portfolio includes consumables, instruments, diagnostic platforms and bioinformatics. FY2021 sales were nearly evenly divided between Molecular Diagnostics and Life Sciences; COVID-19 products represented 31% of sales.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $2,251.7 million | $1,870.3 million |
| Gross profit / gross margin | $1,450.8 million / 64.4% | $1,232.7 million / 65.9% |
| Operating income / margin | $630.1 million / 28.0% | $386.4 million / 20.7% |
| Net income | $512.6 million | $359.2 million |
| Diluted EPS | $2.21 | $1.53 |
| Net cash from operating activities | $639.0 million | $457.8 million |
| Cash used in investing / financing | $202.4 million / $150.4 million | $443.3 million / $50.1 million |
Sales grew 20%; non-COVID product sales rose 24% and COVID-19 product sales rose 14%. Molecular Diagnostics sales increased 27% to $1,143.7 million, while Life Sciences sales increased 15% to $1,108.0 million. Consumables and related revenues grew 23%; instrument sales grew 4%. Favorable currency movements contributed about one percentage point to reported sales growth.
Operating margin improved primarily because restructuring, acquisition, integration and other expenses fell to $27.8 million from $150.0 million in 2020, which included $125.5 million of costs related to the unsuccessful Thermo Fisher acquisition attempt. Gross margin declined 1.5 percentage points, reflecting product mix, capacity investment costs and higher amortization. Research and development expense increased 27% to $190.0 million.
At year-end, cash and cash equivalents were $880.5 million and short-term investments were $184.8 million. Working capital was $592.1 million, down from $1.05 billion in 2020. Long-term debt totaled $1.94 billion, including $847.6 million classified as current; stated debt maturities included $847.6 million in 2022. The company also reported €427 million of undrawn credit facilities. Capital expenditures for property, plant and equipment were $189.9 million, versus $132.8 million in 2020.
QIAGEN repurchased 1.9 million shares for $100.0 million in 2021. It has not paid dividends and does not expect to do so in the foreseeable future.
Material changes and unusual items
- Other income, net declined to $40.7 million from $114.3 million in 2020. FY2021 included a $35.8 million gain related to receipt and sale of Invitae shares and a related hedge; FY2020 included a $123.3 million gain from the ArcherDX transaction.
- QIAGEN paid $53.0 million in November 2021 to settle acquired NeuMoDx litigation with Becton Dickinson; the claims were dismissed. A separate ArcherDX patent-infringement verdict resulted in $4.7 million of accrued damages, and QIAGEN said it planned to appeal.
- Early adoption of ASU 2020-06 in 2021 changed the accounting for convertible instruments and reduced additional paid-in capital by $54.1 million at adoption.
- Goodwill was $2.35 billion and intangible assets were $627.4 million at year-end. The filing reports no goodwill impairment in 2021.
Outlook, commentary and risks
Management expected non-COVID sales to continue growing in 2022, supported by research demand and normalization in clinical testing. It expected COVID-19 product sales to decline from 2021 levels, while remaining prepared to support changing pandemic needs. The filing gives no clear numerical 2022 sales or earnings guidance. Management emphasized investment in its five growth pillars: sample technologies, QuantiFERON, QIAcuity, NeuMoDx and QIAstat-Dx.
Key risks include continued COVID-related supply constraints and higher freight or electronics costs; the Russian invasion of Ukraine, sanctions and related market disruption; currency and interest-rate exposure; dependence on successful product development, regulatory approvals and adoption of automation platforms; reimbursement and research-funding uncertainty; competition and intellectual-property litigation; cybersecurity and privacy risks; and significant debt and refinancing needs. Management noted stable availability for many materials in 2021, but electronics shortages required mitigation and sometimes involved price increases. The company’s 2022 outlook also faced inflation and global supply-demand imbalances.
The company reported effective disclosure controls and internal control over financial reporting. KPMG issued unqualified opinions on the consolidated financial statements and internal controls. The audit identified assessment of unrecognized tax benefits as a critical audit matter; recorded unrecognized tax benefits were $103.6 million at year-end.
Important facts for investors to verify
- Review the debt maturity schedule, especially the $847.6 million current portion, available facilities, and the company’s refinancing plans and cash-conversion terms.
- Track the pace of COVID-19 sales declines against non-COVID growth, and whether investments in the five growth platforms translate into recurring consumables revenue and improved margins.
- Assess gross-margin pressure, capital spending and capacity utilization, alongside the increase in operating cash flow and working-capital decline.
- Follow developments in the ArcherDX appeal, contingent commitments, and the $103.6 million of unrecognized tax benefits.
- Evaluate exposure to Ukraine-related disruption, supply constraints, foreign exchange, and the substantial goodwill and acquired intangible asset balances.